Cardarine GW1516 is a chemical that is synthetically produced. The compound was developed in the 1990s and was first considered a potential treatment for certain conditions, including cardiovascular disease and metabolic conditions. Multiple animal studies have been conducted on the use of this compound, but limited data is available in terms of human Cardarine studies.
What Is GW 501516 (Cardarine)?
Cardarine, often also referred to as GW 1516, is a chemical compound classified as a selective agonist of certain receptors in the human body. The receptors that the compound activates are known as Peroxisome Proliferator-Activator Receptor Beta. These receptors are sometimes also referred to as NR1C2.
The initial scientific publications related to the chemical, made by Ligand and GlaxoSmithKline1, described the compound as a potential treatment for a blood lipid condition known as dyslipidemia. Since this publication, many other potential uses for the compound have been detected.
Due to the potential effects on energy expenditure, primarily noted in studies that involved laboratory rats, many researchers have also turned to the theory of this compound as a research performance enhancement chemical. It has been found that the compound assists in the upregulation of protein expressions that are specifically involved in energy expenditure, suggesting that improvements in physical performance may be experienced with the administration of the compound in a controlled research environment
Some evidence has also shown that the use of GW 501516 may possibly be useful in upregulating the enzyme activity related to the oxidation of fatty acids, particularly in skeletal muscle tissue within the human body2.
In addition to a potential option to be considered in the treatment of heart-related conditions and as a research theoretical performance-enhancement product, suggestions have also been made that the chemical may be useful in the treatment of type 2 diabetes, as well as obesity caused by an inappropriate diet.
The majority of research that has been conducted on Cardarine to date has been on animal models, but this still provides a solid overview of the potential theoretical research benefits that the compound may hold, such as the possibility to assist in the treatment of certain conditions.
One recent study3 provided evidence that activators of the Peroxisome proliferator-activated receptors may hold the potential to act as an antihypertensive agent. What this means is that blood pressure levels could potentially be reduced with the use of a substance like Cardarine. Thus, the use of this chemical may be appropriate for researchers with a condition like hypertension. Hypertension, or high blood pressure, is known to damage blood vessels and may lead to additional complications as well – the reduced blood pressure levels produced through the use of Cardarine may also act as a protective mechanism on a patient’s cardiovascular system.
In another study4, scientists found that the use of compounds like Cardarine that interacts with the particular receptors involved in the administration of the chemical may yield improvements in insulin signaling. This study provided evidence that this particular chemical may be useful in patients with insulin resistance, as well as those patients who have been diagnosed with type 2 diabetes. Improved insulin signaling may help the body better secrete insulin and provides the body with an improved mechanism for utilizing insulin – the hormone that is responsible for carrying glucose through the body.
GW501516 side effects noticed in a controlled research environment
While studies have confirmed multiple benefits of Cardarine, there are several GW 50156 side effects that have also been noted by some animal studies. It is crucial for both researchers and physicians to understand these risks before deciding whether this chemical may be appropriate for a particular controlled research environment.
In one study5, published in the BioMed Central Journal of Cell & Bioscience, scientists discovered one particular risk that needs to be understood by researchers. After testing the effects of Cardarine, they found that the substance may promote a condition known as liver fibrosis.
Best place to buy GW 501516
The majority of Cardarine products on the market today are found to be fake – they do not contain the real chemical known as Cardarine or GW-501516. This makes it difficult to know where to buy the chemical. Generally, it is important to consider the trustworthiness of any source before making a decision to buy a research product that claims to have this particular compound as an active ingredient. Research should be conducted to ensure the supplier is trustworthy and that the product sold by the company is in fact, real Cardarine. Luckily, companies like GenX Peptides conduct 3rd party testing to ensure the purity of their products.
GenX Peptides | Conclusion
The use of Cardarine has been suggested for heart-related conditions, as well as metabolic diseases, but limited studies have been conducted on human subjects. Understanding both the benefits and the potential risks involved with this chemical compound is important for researchers interested in utilizing the compound as a possible treatment solution for conditions that they have developed. At the time of writing this article, this product is only made for research purposes and is not to be consumed by humans.
1 P. Pelton. GW-501516 GlaxoSmithKline/Ligand. Current Opinion in Investigational Drugs. Apr 2006. https://www.ncbi.nlm.nih.gov/pubmed/16625823
2 D.L. Sprecher. Lipids, lipoproteins, and peroxisome proliferator-activated receptor-delta. The American Journal of Cardiology. 3 Dec 2007. https://www.ncbi.nlm.nih.gov/pubmed/18047848
3 M. Toral. Antihypertensive effects of peroxisome proliferator-activated receptor-B/o activation. American Journal of Physiology. 2017. https://www.ncbi.nlm.nih.gov/m/pubmed/27881385/?i=10&from=GW%20501516
4 T. Yoo. Ligand-Dependent Interaction of PPARo With T-Cell Protein Tyrosine Phosphatase 45 Enhances Insulin Signaling. Journal of Diabetes. 2018. https://www.ncbi.nlm.nih.gov/m/pubmed/29233935/?i=5&from=GW%20501516
5 R. Kostadinova, A. Montagner, E. Gouranton, S. Fleury, H. Guillou, D. Dombrowicz, P. Desreumaux, W. Wahli. GW501516-activated PPARB/o promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. BioMed Central Journal of Cell & Bioscience. 10 Oct 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519722/
The information on this website has not been evaluated by the Food & Drug Administration or any other medical body. We do not aim to diagnose, treat, cure or prevent any illness or disease. Information is shared for educational purposes only. You must consult your doctor before acting on any content on this website, especially if you are pregnant, nursing, taking medication, or have a medical condition.